Literature DB >> 1612066

The rationale for glucose control in diabetes mellitus.

D M Nathan1.   

Abstract

After more than 60 years of active investigation, the role of intensive treatment regimens in preventing and ameliorating diabetes complications is close to being resolved. Currently available intensive regimens do not achieve normoglycemia and are associated with significant complications. Moreover, they are dependent on a high level of patient motivation and adherence and may not be widely applicable in the IDDM population. Given these limitations, it is critical that their benefit, if any, be documented before they are introduced widely into clinical therapy. If the glucose hypothesis proves to be true, the benefits of intensive therapy will outweigh all of its limitations. Although previous trials have failed to document benefits with regard to retinopathy (the decrease in the progression from incipient nephropathy to clinical proteinuria is of unknown clinical significance), the DCCT has adequate power to define the role of intensive therapy. If the DCCT demonstrates a salutary effect of intensive therapies, a rationale for such efforts finally will have been established. The goal for the next generation of clinical investigation will be to develop new means of intensive therapy that have less risk and are more accessible and acceptable to all persons with diabetes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612066

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

Review 1.  Use of Automated Bolus Calculators for Diabetes Management.

Authors:  Frank L Schwartz; Cynthia R Marling
Journal:  Eur Endocrinol       Date:  2013-08-23

2.  Acceleration of functional maturation and differentiation of neonatal porcine islet cell monolayers shortly in vitro cocultured with microencapsulated sertoli cells.

Authors:  Francesca Mancuso; Mario Calvitti; Giovanni Luca; Claudio Nastruzzi; Tiziano Baroni; Stefania Mazzitelli; Ennio Becchetti; Iva Arato; Carlo Boselli; Monique D Ngo Nselel; Riccardo Calafiore
Journal:  Stem Cells Int       Date:  2009-11-19       Impact factor: 5.443

3.  Bioactive long-term release from biodegradable microspheres preserves implanted ALG-PLO-ALG microcapsules from in vivo response to purified alginate.

Authors:  Stefano Giovagnoli; Paolo Blasi; Giovanni Luca; Francesca Fallarino; Mario Calvitti; Francesca Mancuso; Maurizio Ricci; Giuseppe Basta; Ennio Becchetti; Carlo Rossi; Riccardo Calafiore
Journal:  Pharm Res       Date:  2009-12-31       Impact factor: 4.200

4.  Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS.

Authors:  Sarah Knippenberg; Nadine Thau; Reinhard Dengler; Thomas Brinker; Susanne Petri
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.